Fuzheng Huayu Tablet in the treatment of Crohn's disease intestinal fibrosis: a prospective, multicenter, randomized controlled study

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200005582

Enrollment

Unknown

Registered

2022-02-01

Start date

2022-02-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

1:standard treatment

3:standard biotherapy

4:standard biotherapy + Fuzheng Huayu

2:standard treatment + Fuzheng Huayu

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Ages 18 to 80 2.Preoperative CDAI score <150 3.Laparoscopic ileocecal resection and one-stage anastomosis were performed 4.The pathological indication is fibrotic stenosis

Exclusion criteria

Exclusion criteria: 1.Smokers who cannot quit smoking 2.Patients with diseases of heart, lung, liver, kidney and other organs 3.Malignant stenosis 4.Allergic to Fuzheng Huayu tablet

Design outcomes

Primary

Measure	Time frame
BMI;CRP;CBC;	—

Countries

China

Contacts

Public ContactChunqiu Chen

wangbingrui@njmu.edu.cn13671864838

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026